The nephroureterectomy: a review of technique and current controversies

Gregory J. Barton¹, Wei Phin Tan¹, Brant A. Inman¹²

¹Division of Urology, Duke University Medical Center, Durham, NC, USA; ²Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA

Contributions: (I) Conception and design: GJ Barton, BA Inman; (II) Administrative support: BA Inman; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: GJ Barton; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Brant A. Inman, MD, MS, FRCSC. Cary N. Robertson Associate Professor of Urologic Oncology, Co-Director of Duke Prostate and Urologic Cancer Center, Vice Chief of Urology, Box 103868, 3007 Snyderman Bldg, 905 La Salle Street, Durham, NC 27710, USA. Email: brant.inman@duke.edu.

Abstract: The nephroureterectomy (NU) is the standard of care for invasive upper tract urothelial carcinoma (UTUC) and has been around for well over one hundred years. Since then new operative techniques have emerged, new technologies have developed, and the surgery continues to evolve and grow. In this article, we review the various surgical techniques, as well as present the literature surrounding current areas of debate surrounding the NU, including the lymphatic drainage of the upper urinary tract, management of UTUC involvement with the adrenals and caval thrombi, surgical management of the distal ureter, the use of intravesical chemotherapy as well as perioperative systemic chemotherapy, as well as various outcome measures. Although much has been studied about the NU, there still is a dearth of level I evidence and the field would benefit from further studies.

Keywords: Upper tract urothelial cancer; nephroureterectomy (NU); outcomes

Submitted Sep 18, 2019. Accepted for publication Dec 02, 2019. doi: 10.21037/tau.2019.12.07

View this article at: http://dx.doi.org/10.21037/tau.2019.12.07

Overview

The nephroureterectomy surgery has been utilized for more than 100 years. In 1898, Dentu and Albarran described the first nephroureterectomy, which only involved removing a portion of the ureter (1). Kimball and Ferris subsequently noted tumor recurrences in the remaining distal portion of the ureter, and expressed the importance of resecting the entire ureter; from renal pelvis to the intramural ureter (2). In 1991 the first laparoscopic nephroureterectomy (LNU) was reported by Clayman (3). The first report of the use of a surgical robot for nephrectomy was reported in 2001, followed by the first robotic assisted heminephroureterectomy in 2004, although this was performed for recurrent infections and incontinence due to ectopic ureters, not upper tract urothelial carcinoma (UTUC) (4,5). In 2006, Nanigian et al. subsequently reported the first robotic-assisted laparoscopic nephroureterectomy (RANU) (6,7). For high-grade UTUC, radical nephroureterectomy has been and still is the standard of care. In this review, we describe the radical nephroureterectomy, specific nuances, areas of debate, outcomes, and the future of the procedure.

Description of technique

Nephroureterectomy is best categorized into two parts of the surgery: (I) radical nephrectomy and (II) distal ureterectomy (8). Each of these parts can be performed with...
an open or minimally invasive approach. Each approach has its own pros and cons as will be described below.

Surgical approach

Open nephroureterectomy (OUN) is the gold standard for the management of high-grade UTUC (9). Although only one randomized controlled trial (RCT) comparing surgical approaches (OUN to LNU) has been performed, many retrospective studies exist (10,11). The majority, including the RCT, report shorter operative times for OUN when compared to LNU, 156–324 vs. 180–498 minutes, respectively (10). Operative time for RANU has not been directly compared to ONU or LNU, but reported times range 184–326 minutes (10). However, estimated blood loss (EBL) and hospital length of stay (LOS) tend to be lower in LNU and RANU than in ONU (130–479 mL and 2.3–13.5 days, 50–284 mL and 2.3–6.7 days, 296–696 mL and 5.2–21.1 days, respectively) (10). Lymph node dissection (LND) is performed less frequently than RANU, but when performed, RANU had higher median node counts, as well as lower perioperative morbidity (12-14). Unfortunately, RANU is more expensive than LNU by ~$5,500 ($23,235 vs. $17,637) (15).

Nephrectomy

In an ONU, single and two-incision techniques have been described. The pros and cons of each approach are detailed in Table 1. If a two-incision technique is used, the patient is placed in the flank position for the nephrectomy portion of the case. The nephrectomy is performed, although the ureter is not divided, just clipped, and after the ureteral dissection is taken as distally as possible (usually to the level of the common iliac artery), the patient needs to be repositioned to the supine position for the distal ureterectomy. Patient positioning for a single incision ureterectomy (midline laparotomy and paramedian laparotomy), the patient remains supine for the entirety of the case; however, for the thoracoabdominal incision, the patient is placed in the flank position for the nephrectomy portion and then is repositioned to supine for the distal ureterectomy (8).

In an LNU, for the skilled laparoscopic surgeon, the entire case can be performed pure lap. However, the distal ureteral dissection and bladder cuff resection can be quite challenging. For this reason, it is not uncommon for surgeons to perform the nephrectomy laparoscopically, and then perform the distal ureterectomy open. In a pure LNU, the patient is placed in a modified flank position and secured to the table in case it needs to be rotated to a supine position for the distal ureterectomy. The distal ureterectomy is better performed pure lap when the tumor is the renal pelvis or proximal ureter, and if the surgeon is skilled at laparoscopy. If the tumor is distal and/or the surgeon is uncomfortable performing the distal ureterectomy laparoscopically, the patient can be repositioned supine following the nephrectomy, and the distal ureterectomy treated in an open fashion. Port placement follows standard laparoscopic principles, wherein the ports are triangulated around the kidney, generally three or four trocars, depending on laterality (for right-sided tumors a fourth subxiphoid trocar for liver retraction can be placed). With obese patients, the template layout is shifted lateral of midline towards the lesion, or else the standard template shifts too far contralateral once the abdomen is insufflated (8).

An alternative to the LNU is the hand-assist laparoscopic nephroureterectomy (HALNU). The HALNU provides for more improved retraction during the nephrectomy which decreases operative time, and the hand port also serves as an extraction site as well as an open approach to the bladder cuff, if desired. Options for the hand port site include midline or Gibson incisions. The midline incision is more comfortable for the surgeon during nephrectomy, but the distal ureterectomy is more difficult. The Gibson incision, although more difficult and potentially uncomfortable during the nephrectomy, allows for a more facile open distal ureterectomy.

The RANU, although similar in technique to the LNU, provides improved visualization (10× magnification) and dexterity, which facilitates LND, as well as distal ureterectomy. However, due to limitations of the robotic arm placement and positioning, following the nephrectomy (performed in the flank position), the earlier platforms of the da Vinci robot (Intuitive Surgical, Inc., Sunnyvale, CA, USA) would need to be undocked, the patient re-positioned to supine, then the robot re-positioned and re-docked, significantly increasing operative time (16). However, with the da Vinci Si platform, novel port placements that eliminate the need for robot redocking were described, and the fourth generation platform, the da Vinci Xi, allows for improved ease with which to perform a single docking RANU, because it allows for the arm boom to swing to accommodate surgical needs, as well as the fact that the camera can be placed in any port, and the ports can be closer to each other than with the da Vinci Si (16-20).
Table 1 Open NU approaches (8)

<table>
<thead>
<tr>
<th>Type</th>
<th>Incision</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single</td>
<td>Thoracoabdominal</td>
<td>Provides access for large masses</td>
<td>Limited contralateral access</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No repositioning</td>
<td>Increased morbidity, very large incision</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Violation of pleural cavity = increased risk of pulmonary complications</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Transects large muscles</td>
</tr>
<tr>
<td>Single</td>
<td>Midline laparotomy</td>
<td>Provides good bilateral access as well as access to aorta and IVC</td>
<td>Poorer access to upper pole</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Does not transect muscles</td>
<td>Large incision</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No repositioning</td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>Paramedian laparotomy</td>
<td>Provides good access to the aorta and IVC</td>
<td>Poorer access to upper pole</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lower hernia rate</td>
<td>Large incision</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Does not transect muscles</td>
<td>Difficult to access contralateral retroperitoneum</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No repositioning</td>
<td>Transects deep inferior epigastrics</td>
</tr>
<tr>
<td>Upper</td>
<td>Flank</td>
<td>Allows for extraperitoneal approach</td>
<td>Requires repositioning for distal ureterectomy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Difficult LND</td>
</tr>
<tr>
<td>Upper</td>
<td>Subcostal</td>
<td>Good access to hilar vessels</td>
<td>Requires repositioning for distal ureterectomy</td>
</tr>
<tr>
<td>Lower</td>
<td>Gibson</td>
<td>Can perform distal ureterectomy through it</td>
<td>Less comfortable for HALNU</td>
</tr>
<tr>
<td></td>
<td>Midline or Pfannenstiel</td>
<td>No muscle transection</td>
<td>Will need to reposition from flank/subcostal incision</td>
</tr>
</tbody>
</table>

NU, nephroureterectomy; IVC, inferior vena cava; LND, lymph node dissection; HALNU, hand-assist laparoscopic nephroureterectomy.

**Distal ureterectomy**

The distal ureter and bladder cuff can be managed with an open, laparoscopic, or endoscopic method (21). Currently, there are no prospective RCTs comparing the approaches. The standard of care is complete resection of the entire distal ureter with a cuff of surrounding bladder tissue (9). Poorer cancer-specific survival (CSS) and overall survival (OS) has been seen in patients who did not have a bladder cuff excision (BCE) during their NU (22,23). Furthermore, Phé et al. noted the importance of BCE on oncologic outcomes when reviewing the distal ureter management options (21). Some smaller studies call this into question, and as such they should be interpreted with caution. Ha et al. found no difference in CSS based on BCE status for all UTUC patients; however, when stratified by tumor location, BCE was associated with improved CSS with ureteral tumors but not with renal pelvis tumors (24). Lughezzani et al. found that with renal pelvis tumors, BCE improved CSS with \( \geq pT3 \) and/or \( pN+ \) patients, but there was no difference with \( \leq pT2 \) disease (25). Despite standard of care practices for BCE, not all urologists perform one. In a recent analysis of Surveillance, Epidemiology and End Results (SEER) data, Nazzani et al. found that in only 68% of 4,266 patients had a BCE at time of NU. Interestingly, they saw no difference in CSS regardless of BCE status (26).

Open distal ureterectomy has historically been considered the gold standard in NU because it allows for maximal control of distal ureteral disease during the procedure (27). Even in an LNU, surgeons may opt to still manage the distal ureter and bladder cuff in an open fashion. The HALNU lends itself to open management via the hand port incision, as noted above. However, significant controversy exists over the optimal approach to management.

In an open distal ureterectomy, the surgeon has the option to perform an intravesical or extravesical approach to remove the ureter and bladder cuff. The intravesical technique allows for excellent visualization of the intramural
ureter and bladder cuff, but at the expense of increased morbidity and longer catheterization owing to the two cystotomies required (21). A low midline incision is made, followed by an anterior cystotomy, which allows the surgeon to directly visualize the ureteral orifice and surrounding bladder cuff, shown in Figure 1. A circular incision is made 5–10 mm around the ureteric orifice and the intramural ureter is dissected until the proximal ureteral dissection is reached, allowing the specimen to be removed en bloc. The posterior and anterior bladder walls are then each closed in two layers.

The extravesical technique, shown in Figure 2 is less morbid, but visualization is poorer and the dissection of the intramural ureter and bladder cuff resection can be much more difficult, especially if a suboptimal incision is made (21). To start, a small low midline incision or Gibson incision is made and after identifying the ureter as it crosses the iliac vessels, the dissection continues distally to the intramural ureter, which is dissected out along with a 5–10-mm bladder cuff. The specimen is removed en bloc and the bladder is closed in two layers.

Laparoscopic approaches generally utilize an extravesical approach. To complete the entire distal ureterectomy laparoscopically requires a skilled laparoscopic surgeon (21). A transvesical laparoscopic approach, using transvesically placed trocars to allow for passage of a resectoscope to perform a distal ureterectomy, has been described but is not widely used due to its difficulty (21).

Options for endoscopic management of the distal ureter/bladder cuff include transurethral resection of the ureteral orifice (Pluck technique) and ureteral intussusception (Stripping technique). There are few studies comparing the different endoscopic approaches. Laguna et al. compared the endoscopic pluck to ureteral stripping and found no significant differences in intravesical recurrence-free survival (IVRS) between the two, but noted a higher complication rate with stripping (10% vs. 2.7%) (28). The Pluck and Stripping techniques should not be used for distal or midureteral tumors due to the risk of tumor spillage and seeding. However, these approaches are designed to maximize the ease of the distal ureterectomy without the morbidity of larger incisions; both are performed with the patient in lithotomy (8). With endoscopic approaches, if the bladder is not closed, there is a risk of urine (and possibly tumor cell) spillage.

With the Pluck technique, either a Collins knife or loop resectoscope is used to circumferentially incise a 5–10-mm cuff of bladder mucosa surrounding the ureteral orifice, shown in Figure 3. A urethral catheter is placed to minimize urine seepage through the residual cystotomy during the remainder of the case (8).

With the Stripping technique, a ureteral catheter is placed and the nephrectomy portion is then performed. The ureter is dissected as distally as possible, and then ligated cranial to the end of the ureteral catheter. Following
that, the ureter is cut between the ligation and the ureteral catheter. The ureteral catheter is pulled out of the end of the ureter, folded over itself, then secured to the ureter; this is shown in Figure 4. The patient is then placed back in lithotomy, a resectoscope is inserted, and the intramural ureter is resected to the peri-vesical fat. The catheter is then pulled out, bringing the intussuscepted ureter with it. A urethral catheter is placed and the bladder closes by secondary intention.

Many studies have attempted to compare outcomes between endoscopic approaches to open approaches to BCE management, with no clear consensus regarding optimal management. When comparing the approaches, a number of studies have found no difference in CSS or OS (29-36). However, these studies demonstrate differing findings with regards to intravesical recurrences (IVRs), or IVRS. In some studies, endoscopic management is associated with poorer IVRS (30,32,36). Alternatively, no difference in IVRS is seen in competing studies (23,29,31,35,37).

To further complicate the picture, some of those studies stratified their analyses by comparing intravesical (anterior cystotomy approach) to extravesical to endoscopic management and none were in complete agreement (29-31,36,38). Xylinas et al. reported no significant difference between any of the approaches with regards to recurrence-free survival (RFS), CSS, or OS; but endoscopic management was associated with poorer IVRS when compared to either extravesical or intravesical management (36). Lee et al. reported that intravesical and extravesical management was associated with superior RFS and IVRS when compared to endoscopic management (39). Kapoor et al. found that intravesical management had superior RFS to either extravesical or endoscopic management, and interestingly, endoscopic and intravesical management was associated with better IVRS than extravesical management (38). To round out the differences, Allard et al. and Li et al. found no difference among any of the approaches with regards to RFS or IVRS (29,31). Last, both Fragkoulis et al. and Walton et al. reported shorter operative times with endoscopic management (35,37).

**Topics of debate**

While the surgical techniques described above are generally well accepted in the urologic community, there remains a number of factors related to the NU that require specific attention or engender strong debate. These are described further below.

**Lymphatic drainage & nodal management**

It is thought that the lymphatic drainage of the upper
recently published a review that found no difference in survival outcomes for LND. They suggested that removing hilar, paracaval, and retrocaval nodes (41). In a follow up study assessing the impact of LND templates, he found that retaining hilar, paracaval, retrocaval, and interaortocaval lymph nodes for right renal pelvis and upper/mid ureteral tumors was associated with improved CSS (42).

In 2017, he described a lower ureteral tumor lymph node template regardless of tumor laterality, consisting of the common iliac, internal and external iliac, obturator, and presacral lymph nodes; however, no difference in RFS or CSS was seen with templated LND for lower ureteral tumors, despite improved RFS and CSS with templated LND for renal pelvis and upper/mid ureteral tumors (43).

Alvarez-Maestro et al. recently published a review of lymph node metastatic spread and noted predictable patterns similar to that of Kondo et al. (40). Matin et al. also noted similar metastatic patterns, importantly reporting that the right renal pelvis also drained to the inter-aortocaval lymph nodes, something that Kondo did not note in his 2007 study, but incorporated in later studies (44). The lymph node templates and outcomes are detailed in Table 2 and drainage patterns and visual representations of the templates are detailed in Figures 5,6, respectively.

Despite descriptions of LND templates, there are no prospective RCT on nodal management with UTUC. In 1997 Komatsu et al. first published the results of their experience with 36 patients who underwent NU with LND; 5-year OS for pN+ patients was 21%, but there were no disease related pT0 patient deaths. They suggested that LND may provide some therapeutic benefit to select, low volume patients and may be a useful in staging UTUC (45). This conclusion was supported later by Roscigno et al. in 2011 in a larger review (46). Soon after, Miyake et al. described a retrospective series of 72 patients who underwent NU for UTUC, with 35 undergoing LND and 38 without LND. They found that there was no difference in OS when the two cohorts were compared; however, in patients without lymphovascular invasion, LND was associated with improved OS (47). This sparked a number of small studies assessing the oncologic outcomes associated with LND and LND yield, which are detailed in Table 3.

Multiple recent systematic reviews found that LND with advanced disease (≥ pT2 or ≥ pT3) was associated with improved CSS and increased lymph node yield (LNY) was associated with decreased mortality (52,55,58,59). This culminated with a systematic review by the European Association of Urology (EAU) guidelines panel, who found that both template-based and complete LND improves tumor staging as well as CSS with ≥ pT2 UTUC and reduces local recurrences. They also reported incidences of pN+ in cN0 ≥ pT2 patients ranging from 14.3% to 40% (54).

However, several other large-scale studies recently have found no improvement in CSS with LND. In a 2010 study of 2,824 SEER patients, Lugezzanni et al. found no difference in 5-year CSS with pN0 vs. pNx patients (81.2% vs. 77.8%). They did concede that a lack of standardized criteria for LND selection was a possible explanation for the lack of difference (50). Mason et al. studied 1,029 patients who underwent NU +/− LND and found no survival difference between pN0 and pNx patients; however, only a small proportion (n=276) were +LND (51). Inokuchi et al. retrospectively reviewed a multi-institutional cohort of 2,037 patients and found poorer OS with pN+ patients (estimated 5-year OS 30%); however, on multivariable analysis no improvement in CSS or OS was seen with LND, (median LNY =6) (56). It should be noted that in these studies, the authors largely compared pNx to pN0, with few pN+ patients, which may explain the lack of improvement in survival outcomes for LND.

In 2018, Guo et al. published an extensive systematic review and meta-analysis, the first meta-analysis on this subject, of 11 studies and 7,516 patients. They found no difference in hazard ratio (HR) between +LND and non-LND (NLND) groups, as well as no difference in CSS between pN0 and pNx patients. Even with subgroup analysis, no difference in RFS for LND or NLND ≥ pT2 patients. However, improved CSS (HR =3.38) was seen when comparing pN0 to pN+ patients. Based on these results, the authors concluded that LND does allow for more accurate staging and survival prediction, but its independent impact on survival remained unclear (57). Indeed, while the EAU guidelines on UTUC agree that LND allows for improved staging of UTUC, they recommend against LND in superficial UTUC (pTa/
Table 2 Lymph node drainage/dissection templates

<table>
<thead>
<tr>
<th>Study</th>
<th>Lymph node drainage/template (based on primary tumor site)</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Renal pelvis</td>
<td>Upper/mid ureter</td>
</tr>
<tr>
<td>Kondo 2007* (41)</td>
<td>H, PC, RC</td>
<td>RC, IAC</td>
</tr>
<tr>
<td>Matin 2015* (44)</td>
<td>H, PC, RC, IAC</td>
<td>H, PC, RC**</td>
</tr>
<tr>
<td>Kondo 2017 (43)</td>
<td>H, PC, RC, IAC</td>
<td>H, PC, RC, IAC</td>
</tr>
</tbody>
</table>

*, this study only reported lymph node metastatic drainage patterns; **, for upper ureteral tumors; *** for mid ureteral tumors. H, hilar lymph nodes; PC, paracaval lymph nodes; RC, retrocaval lymph nodes; IAC, interaortocaval lymph nodes; PA, para-aortic lymph nodes; CI, common iliac lymph nodes; II, internal iliac lymph nodes; EI, external iliac lymph nodes; O, obturator lymph nodes; PS, presacral lymph nodes; RFS, recurrence-free survival; CSS, cancer-specific survival; LND, lymph node dissection.

and provide a grade C recommendation for LND in invasive (≥ pT2) UTUC (27). A prospective RCT would assist in elucidating the impact of LND on survival in patients with UTUC, if any.

Adrenal management

Adrenal metastasis of UTUC is exceedingly uncommon; in an analysis of LNU outcomes, only one adrenal metastasis was reported in a cohort of 116 patients (60). In the past three decades there has been only one study assessing the utility of adrenalectomy at time of NU for UTUC. Huang et al. reported on 110 patients who underwent NU for UTUC, of which 40 had concurrent ipsilateral adrenalectomy at the time of NU (based on surgeon preference). No adrenal metastases were reported in the adrenalectomy cohort on pathologic analysis at time of surgery. In the entire cohort of 110, 10 patients developed distant metastases (5 in adrenalectomy and 5 in adrenal sparing) and none were located in the adrenal gland or adrenal fossa (61). If pre-operative imaging demonstrates adrenal involvement, or the adrenal appears abnormal intra-operatively, adrenalectomy should be performed, otherwise ipsilateral adrenalectomy at time of NU likely can be safely omitted; however, we lack level 1 evidence supporting this practice.

Vena cava thrombus management

Similar to metastatic adrenal metastatic spread, UTUC is rarely associated with a vena cava thrombus; fewer than 50 cases are reported in the literature, largely consisting of case reports owing to its rarity. Li et al. published a case report of their experience but included a literature review of the topic of studies from 1972 to 2016. They reviewed 48 cases of UTUC with vena cava thrombus; 22 patients died dead (ranging from death immediately after surgery to alive for 60 months), 14 with no evidence of disease, and 14 with no recorded follow-up (62). Similarly, Singh et al. reported a case report and literature review, reporting that the prognosis of UTUC with caval thrombi was poorer than with renal
Figure 5  The lymphatic drainage patterns for UTUC. (A) Drainage of the right renal pelvis (paracaval > hilar > interaortocaval > retrocaval); (B) drainage of the left renal pelvis (hilar > para-aortic > interaortocaval > other); (C) drainage of the right proximal ureter (hilar = paracaval > retrocaval); (D) drainage of the left proximal ureter (para-aortic > hilar); (E) drainage of the left mid ureter (para-aortic > hilar); (F) drainage of the right distal ureter (pelvic); (G) drainage of the left distal ureter (pelvic).

cell carcinoma; >50% of patients with UTUC associated caval thrombi were dead within a year of surgery (63). The surgical management does not differ based on UTUC versus renal cell carcinoma primary; however, the paucity of cases restricts extensive review of various surgical techniques (64-68). Variant histology is not common, but when present, sarcomatoid differentiation is most commonly seen, although it is less common in general (69-71).

Ureter management

A grade A recommendation from the EAU for diagnostic workup for UTUC consists of cystoscopy, urine cytology, and CT urography. However, diagnostic ureteroscopy (URS) only receives a grade C recommendation (27). With URS and UTUC, concerns arise regarding the risk of tumor recurrence and/or urothelial cancer cell seeding elsewhere in the urinary tract, as well as the risk of URS delaying NU and negatively affecting outcomes.

Recently, three systematic review and meta-analyses have been conducted to study the effect of pre-operative URS on oncologic outcomes following NU. Tan et al., Guo et al., and Liu et al. reviewed 11, 8, and 9 high quality studies, respectively, all of which retrospectively reviewed ureteroscopic impact on IVRS, CSS, metastasis-free survival (MFS), and OS following NU. In all three reviews, URS was negatively associated with IVRS (HR 1.42–1.81) by roughly 40–80%. URS did not significantly impact MFS or OS, and with Tan and Liu, URS also did not affect CSS (72-74). Interestingly, Guo reported an increased CSS with URS pre-operatively (HR 0.76), but felt that this was due to selection bias, as patients with more advanced disease (and therefore poorer prognoses) would have a less equivocal diagnostic workup and would proceed directly to NU (72).

Although these reviews found largely no URS impact on oncologic outcomes, with the exception of IVRS, no mention was made of the timing of the procedures. Urothelial cancer, especially high grade or invasive, should
Figure 6 Proposed lymph node dissection templates. (A) Dissection template for right renal pelvis and proximal ureteral tumors; (B) dissection template for left renal pelvis and proximal ureteral tumors; (C) dissection template for right mid ureteral tumors; (D) dissection template for left mid ureteral tumors; (E) dissection template for right distal ureteral tumors; (F) dissection template for left distal ureteral tumors.

be treated in the most reasonably expeditious fashion, which may not always be possible for a number of reasons, such as the ability of the health care system to provide care (e.g., surgeon schedule, access to appropriate specialist, OR availability) or the desire to give neoadjuvant chemotherapy (NAC) [especially if adjuvant chemotherapy (AC) may not be possible]. To this end, Boorjian et al., Sundi et al. and Xia, et al. studied the impact of delay of NU due to URS on oncologic outcomes (75-77).

Boorjian stratified patients by NU alone (n=34), URS for biopsy followed by NU (n=75), and URS followed by ablation and ultimately NU (n=12). Mean time to from URS and biopsy to NU was 28 days, and from ablation to NU was 196 days. CSS, MFS, or OS did not differ among the groups (75). As the decision for timing was surgeon-dependent, this may support the notion that if deemed appropriate by the surgeon, superficial/low grade UTUC can safely be managed in a staged manner.

Sundi stratified patients by “early” and “delayed” treatment following URS. Early (n=186) and delayed (n=54) were defined by <3 or >3 months between URS and extirpative surgery. Reasons for delay included administration of NAC (n=27) or surveillance (n=9). There was no difference in CSS or OS if surgery was delayed following URS (76). Even with subgroup analysis that removed NAC patients, CSS and OS were not affected by delay >3 months. It should be noted that the median time to surgery in the delayed group was not reported and the authors concluded that this demonstrated it was safe to delay surgery for NAC; no conclusions should be drawn regarding safety of long-term delay of NU or ureterectomy.

Fortunately, Xia et al. stratified patients six groups based on timing between URS and NU: ≤7, 8–30, 31–60, 61–90, 91–120, and 121–180 days. With the exception of the longest delay group, 121–180 days, timing was not associated with OS. However, patients delayed 121–180 days did have poorer OS compared to a wait time of 8–30 days (HR 1.61). Patients in the 121–180-day group were older, more likely to be treated at academic centers, and more likely to have ≥ pT2 disease. However, a similar poorer OS
<table>
<thead>
<tr>
<th>Study</th>
<th>Study type</th>
<th>N</th>
<th>Yes LND</th>
<th>No LND</th>
<th>Outcomes</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Komatsu 1997 (45)</td>
<td>Retrospective review</td>
<td>36</td>
<td>36</td>
<td>–</td>
<td>pN+ 5-year OS =21%</td>
<td>No disease-related pT0 deaths</td>
</tr>
<tr>
<td>Miyake 1998 (47)</td>
<td>Retrospective review</td>
<td>72</td>
<td>35</td>
<td>37</td>
<td>5-year OS pN+ =0%</td>
<td>LND not associated with improved OS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5-year OS + LND =58%</td>
<td>pN+ poorer outcomes than pN0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5-year OS – LND =50%</td>
<td></td>
</tr>
<tr>
<td>Roscigno 2008 (48)</td>
<td>Retrospective review</td>
<td>132</td>
<td>95</td>
<td>37</td>
<td>5-year CSS pN+ &lt; pN0 (48% vs. 73%, P=0.001)</td>
<td>Improved OS with pN0, no difference in OS for pN+ and pNx</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5-year CSS pN+ =39%</td>
<td></td>
</tr>
<tr>
<td>Roscigno 2009 (49)</td>
<td>Multi-institutional</td>
<td>1,130</td>
<td>552</td>
<td>578</td>
<td>5-year CSS pN+ vs. pNx =35% vs. 69% (P&lt;0.001)</td>
<td>CSS did not differ b/t pN0 and pNx for pT1, but pNx was worse for pT2–4</td>
</tr>
<tr>
<td></td>
<td>retrospective review</td>
<td></td>
<td></td>
<td></td>
<td>5-year CSS pNx vs. pN0 =69% vs. 77% (P=0.024)</td>
<td></td>
</tr>
<tr>
<td>Lughezzani 2010 (50)</td>
<td>SEER review</td>
<td>2,824</td>
<td>1,835</td>
<td>747</td>
<td>5-year CSS pNx =81%</td>
<td>No survival benefit related to LND in pN0 when compared to pNx</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5-year CSS pN0 =78%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CSS pNx vs. pN0 (HR: 1.19, P=0.09)</td>
<td></td>
</tr>
<tr>
<td>Mason 2012 (51)</td>
<td>Multi-institutional</td>
<td>1,029</td>
<td>276</td>
<td>753</td>
<td>pN+ vs. pNx OS HR 2.70; DSS HR 2.83; RFS 2.03</td>
<td>LND appears to provide more accurate staging and survival predictions; unclear if LND independently improves survival</td>
</tr>
<tr>
<td></td>
<td>retrospective review</td>
<td></td>
<td></td>
<td></td>
<td>pN+ vs. pN0 OS HR 2.97; DSS 2.94; RFS 2.01</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>pN0 vs. pNx no difference in OS, DSS, RFS</td>
<td></td>
</tr>
<tr>
<td>Yang 2014 (52)</td>
<td>Systematic review</td>
<td>5,739</td>
<td>3,243</td>
<td>2,496</td>
<td>All patients + LND vs. – LND HR 0.95</td>
<td>No CSS difference in all patients, but significant improvement seen with pT2–4 patients on subgroup analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>pT2–4 + LND vs. – LND CSS HR 2.19 (P=0.005)</td>
<td></td>
</tr>
<tr>
<td>Chappidi 2016 (53)</td>
<td>SEER review</td>
<td>2,862</td>
<td>721</td>
<td>2,141</td>
<td>1st quartile LN removed 5-year CSS 78%</td>
<td>Increased LN yield associated with improved CSS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2nd/3rd quartile LN removed 5-year CSS 60%</td>
<td></td>
</tr>
<tr>
<td>Dominguez-Escrig 2017 (54)</td>
<td>Systematic review</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Renal pelvis ≥ pT2c + LND vs. – LND 3-year CSS 90% vs. 52% (HR 0.23, P=0.01)</td>
<td>Survival benefit to LND was seen with high stage renal pelvis UTUC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ureteral tumor + LND vs. – LND 3-year CSS 54% vs. 72% (HR 0.99, P=0.99)</td>
<td>Unclear benefit to ureteral tumors</td>
</tr>
</tbody>
</table>

Table 3 (continued)
Table 3 (continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Study type</th>
<th>N</th>
<th>Yes LND</th>
<th>No LND</th>
<th>Outcomes</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ikeda 2017 (55)</td>
<td>Retrospective review</td>
<td>399</td>
<td>222</td>
<td>177</td>
<td>5-year DFS: pN0 &gt; pNx &gt; pN+ (78% vs. 62% vs. 33%)</td>
<td>Improved DFS and CSS with ≥ pT3 pN0 vs. pNx tumors</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5-year CSS: pN0 &gt; pNx &gt; pN+ (85% vs. 73% vs. 44%)</td>
<td>No difference in DFS or CSS for pT2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥ pT3 pN0 vs. pNx DFS =66% vs. 37%; CSS =76% vs. 46%; P=0.001</td>
<td></td>
</tr>
<tr>
<td>Inokuchi 2017 (56)</td>
<td>Multi-institutional retrospective</td>
<td>2,037</td>
<td>1,046</td>
<td>991</td>
<td>5-year CSS + LND vs. – LND: HR =1.36 (0.88–2.09)</td>
<td>No therapeutic benefit to LND although it may provide improved ability to predict prognosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5-year OS + LND vs. – LND: HR =1.28 (0.87–1.89)</td>
<td></td>
</tr>
<tr>
<td>Guo 2018 (57)</td>
<td>Systematic review</td>
<td>7,516</td>
<td>–</td>
<td>–</td>
<td>CSS pN+ vs. pN0: HR =3.38 (1.94–5.89)</td>
<td>LND allows for improved staging and prognosis prediction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RFS pN+ vs. pN0: HR =3.46 (2.00–5.97)</td>
<td>Survival benefit unclear</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥ pT2 CSS pN+ vs. pN0: HR =3.27 (2.83–3.78)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥ pT2 DFS pN+ vs. pN0: HR =2.10 (1.05–4.20)</td>
<td></td>
</tr>
</tbody>
</table>

LND, lymph node dissection; OS, overall survival; CSS, cancer-specific survival; SEER, Surveillance, Epidemiology and End Results; HR, hazard ratio; RFS, recurrence-free survival; DSS, disease-specific survival; LN, lymph node; UTUC, upper tract urothelial carcinoma; DFS, disease-free survival.

also seen on subgroup analysis with higher risk patients (HR 1.56) (77).

The practicing urologist should be aware that URS before NU increases IVR rates but otherwise does not negatively impact CSS, MFS, or OS. Additionally, although the available evidence is all retrospective in nature, reasonable delays in surgery (i.e., <121 days) do not seem to negatively affect oncologic outcomes. There is a need for prospective data in all respects regarding URS and NU, especially focusing on interventions to decrease IVR, perhaps studying the impact of prophylactic perioperative intravesical chemotherapy.

**Intravesical chemotherapy**

Urothelial carcinoma has a propensity to recur, regardless of initial location in the urinary tract. Reported bladder recurrence rates following NU range from 15–50% (78-80). The field change and intraluminal seeding hypotheses are the two leading hypotheses for mechanism of recurrence, although with new data the intraluminal seeding is becoming more prevalent (81). The field change hypothesis proposes that the urothelium is broadly exposed to carcinogens or there is/are inherent mutations and/or defects in the urothelium and multifocal tumors recur from independent clones of altered cells (82,83). Intraluminal seeding proposes that recurrent urothelial tumors are clones of the initial altered cell, and recurrences arise from intraluminal tumor cell spread (83-86). If this is the mechanism by which recurrence occurs, then it follows that intravesical chemotherapy may be effective in preventing recurrence (87).

The use of intravesical chemotherapy to prevent bladder recurrences following NU for UTUC was first reported by Tari et al. in 1987, who administered a variety of intravesical chemotherapeutic agents [mitomycin C (MMC), carboquone/cytosine arabinoside, or adriamycin] for 2 years post-operatively; only two patients suffered a bladder recurrence during that time (88). However, the use of a single post-operative dose of intravesical chemotherapy was not reported in a prospective fashion until Sakamoto et al. in 2001, who reported on 25 patients receiving MMC.
20 mg plus cytosine arabinoside (89). Multiple systematic reviews and meta-analyses have all shown that a single dose of prophylactic intravesical chemotherapy post-operatively is associated with a ~50% decrease in IVR (81,90,91).

Despite the above, it was only recently, in 2015, that the EAU released an update to the UTUC guidelines, giving a grade B recommendation to administer a single dose of post-operative chemotherapy following NU (27). This recommendation was based on two RCTs that showed a 52% decreased risk of bladder recurrence with an absolute risk reduction (ARR) in bladder recurrence of 13%, following instillation of a single dose of intravesical chemotherapy within 10 days of NU (81,92-94).

The ODMIT-C trial was the first RCT to explore the effect of intravesical chemotherapy on post NU IVR. Two hundred and eighty-four patients undergoing NU for UTUC were randomized to standard post-operative care, or to receive a single dose of post-operative intravesical MMC. The primary end point was incidence of bladder cancer in the first 12 months following NU. In the final intention to treat analysis, 21 of 120 patients (18%) who received post-op MMC, while 32 of 119 patients (27%) who did not receive post-op MMC had a bladder recurrence in the first 12 months following NU (P=0.055). However, on treatment as per protocol analysis, 16% of MMC receiving patients and 27% of control patients suffered a bladder recurrence in the first 12 months (P=0.03). They calculated an ARR of 11% and relative risk reduction (RRR) of 40%, and a number needed to treat (NNT) of 9 (93).

Ito et al. performed a similar trial in 2013, investigating the effect of post-operative intravesical chemotherapy on bladder recurrences following NU. In contrast to the ODMIT-C study, they used intravesical pirarubicin instead of MMC, and specified that intravesical chemotherapy was to be instilled within 48 hours postoperatively. They also found decreased incidence of IVRs with intravesical chemotherapy, noting a HR of 0.26 (92). This was a phase II trial investigating the use of pirarubicin; the study group was, as of this writing, currently recruiting for a phase III trial investigating its use (95).

However, despite level 1 evidence, a growing body of retrospective data, and governing body recommendations for post-operative intravesical chemotherapy following NU, many urologists still do not administer perioperative intravesical chemotherapy. A recent survey of urologists who routinely perform NU in the USA showed that only ~51% administer post-op intravesical chemotherapy (87). Commonly cited reasons for not administering it were lack of evidence to support its use (the most frequently cited reason), concerns regarding patient morbidity and toxicity, and office infrastructure not conducive to its use.

Additionally, some urologists suspect the timing of intravesical chemotherapy is important. Both ODMIT-C and Ito’s trial administered post-operative intravesical chemotherapy due to concerns about spillage into the operative field. Some theorize that intra-operative intravesical chemotherapy is superior, and Moriarty et al. demonstrated that intra-operative intravesical chemotherapy was safe to administer. In their study, MMC was instilled at the start of the surgery and then drained just before the bladder cuff was resected, with no major (≥ Clavien grade 3) complications noted (96). A small retrospective review comparing intra-operative to post-operative intravesical chemotherapy by Noennig et al. found that intra-operative chemotherapy (MMC instilled at the start of surgery and drained just before the distal ureterectomy) had superior IVRS compared to post-operative (HR 0.113) (97). Currently, a phase II trial studying the timing of intravesical MMC is enrolling (NCT03658304).

Chemotherapy

Although there is good evidence supporting the use of cisplatin-based NAC in muscle-invasive urothelial carcinoma of the bladder (UCB), similar evidence for perioperative chemotherapy (PC) with either NAC or AC in UTUC is lacking (98,99). Due to limited number of studies examining this subject, and the lack of level 1 evidence, there are no EAU, AUA, or the National Comprehensive Cancer Network (NCCN) guidelines regarding the use of PC with UTUC.

The available literature is mixed regarding the efficacy of PC. Several large studies noted no impact of PC on survival outcomes (100,101). These findings were contraindicated in other retrospective reviews published around the same time (102-105). More recently, a greater proportion retrospective studies are suggesting a survival benefit with the use of PC, including a number of systematic reviews and meta-analyses (106-115). However, this is contradicted by Necchi et al. who, in 2018, published findings from a multicenter retrospective review of 1,544 patients, and noted no improvement in survival with AC for UTUC (116).

Use of PC has increased with time. In an National Cancer Database (NCDB) review, Gin et al. reported that the use of PC with UTUC had increased from 9.6% to 13.8% from 2004 to 2013, with the increase largely due to
an increase in NAC administration (0.7% to 2.1%), as AC administration remained stable (~11%) (117). No mention was made of the type of PC administered in that study, but Cohen et al. published a similar study utilizing SEER-Medicare data from 2002 to 2011 with similar findings: 13.6% PC administration rate of which 1.8% was NAC and 11.8% AC (118). In this analysis, carboplatin/gemcitabine was most frequently used (42%), followed by gemcitabine/cisplatin (G/C) (22%), carboplatin/paclitaxel (16%), with methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) used the least (<4%).

As there are limited data in general regarding the efficacy of PC for UTUC, similarly there is a paucity of data to direct use as to which type of PC is optimal. Guidelines for muscle-invasive bladder cancer (MIBC) generally recommend platinum-based regimens (cisplatin or carboplatin), with cisplatin recommended for NAC, and these guidelines help inform use in UTUC (99). Historically, MVAC was the predominant AC regimen, but after 2008, G/C and other chemotherapy regimens began to take greater prominence (113). Although sparse, some data support MVAC over other regimens. Ikeda et al. found improved 5-year CSS for high risk patients (e.g., ≥3 risk factors) with the use of AC with MVAC when compared to either AC with G/C or no AC. Risk factors to stratify risk status are listed in Table 4. Importantly, CSS benefit was not seen with G/C for AC, nor with any AC for low or intermediate risk disease (110). Shirotake et al. also found improved RFS and CSS for high risk patients receiving MVAC for AC, while those receiving G/C or no AC did not show a benefit (104). All other studies noting a benefit to PC did not report data supporting one chemotherapy regimen compared to another. The majority of studies utilized platinum-based chemotherapy, and cisplatin-based in renal function allowed; carboplatin was largely reserved for patients unable to tolerate cisplatin (102,103,105,108,109,112).

It is unclear if there is benefit with NAC, AC, or both. Those in favor of NAC argue that that it can treat micrometastatic disease, ideally lead to pathologic downstaging and/or complete pathologic response, and patients may no longer be candidates for cisplatin-based therapy following NU (101,106). In fact, Yafi et al. reported in a cohort of 1,029 patients, 49% were cisplatin-eligible preoperatively, but only 18% post-operatively (101). However, opponents argue that UTUC and UCB may respond differently chemotherapy as there are notable cellular and DNA differences between the two, and as such data for UCB cannot be extrapolated to UTUC (102,107). Furthermore, accurate staging is notoriously more difficult for UTUC and as such NAC administration may lead to over treatment of patients who may not benefit from it (107).

Proponents of AC argue that appropriate patient selection is aided by having pathology, thus low stage patients can avoid unnecessary chemotherapy (107).

In an NCDB review of 6,174 patients, Almassi et al. found that pathologic response significantly increased with NAC [odds ratio (OR) 19.8] (106). Similar improvements in pathologic response (~14%) with NAC were noted by Aziz et al. in a systematic review and meta-analysis (107). Kim et al. recently published a systematic review and meta-analysis of 4 trials (n=318) studying the impact of NAC on survival outcomes, finding that NAC was associated with absolute improvements of 13%, 18%, and 11% for progression-free survival (PFS), CSS, and OS, respectively, when compared to no NAC (111). Interestingly, Hosogoe et al. showed a survival benefit with NAC in clinical node positive patients for PFS (HR 0.32), CSS (HR 0.34), and OS (HR 0.39) (109). Smaller studies also showed survival benefit to NAC (103,112). These are detailed in Table 5.

The use of AC in UTUC has been studied to a greater extent than NAC; a systematic review and meta-analysis by Gregg et al. reviewed 13 studies (n=4,642), of which 11 focused on AC, and found an improvement in OS (HR 0.75), DFS (HR 0.54), and CSS (HR 0.69) with PC (108). Similar findings were demonstrated in a systematic review and meta-analysis by Leow et al., finding cisplatin-based AC associated with improved OS (HR 0.43), DFS (HR 0.49), but not CSS (102). In an NCDB review of 3,252 patients, Seisen et al. also noted improvement in OS with AC (median survival 41.41 vs. 35.78 months, P<0.001) (115). Similar improvement in survival outcomes with the use of AC was also seen in individual studies.

---

**Table 4** UTUC risk factors for risk stratification (110)

<table>
<thead>
<tr>
<th>Risk factor (low risk =0; intermediate risk =1–2; high risk group ≥3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥pT3</td>
</tr>
</tbody>
</table>

UTUC, upper tract urothelial carcinoma; LVI, lymphovascular invasion.
(104, 105, 110, 113). Even in metastatic UTUC, Seisen et al. demonstrated improvement in 3-year OS with the use of PC and NU when compared to just chemotherapy (16.2% vs. 6.4%; P<0.001) (120). However, unlike NAC, there are studies that show no benefit with the use of AC. The largest of these is a recent retrospective review by Necchi et al. which reviewed 1,544 patients, 312 of whom received AC (~75% cisplatin-based), and found no difference with OS for patients receiving AC and those who didn’t (116). Another large review by Yafi et al. of 1,029 patients also found no association with improved OS or CSS with the use of AC (101). These studies are displayed in Table 6.

Recently, level 1 evidence has been presented in abstract form. The POUT trial, a prospective, RCT studying the impact of PC on survival outcomes (specifically PFS), was recently presented and was notable for finding a significant improvement in PFS with PFS (HR 0.47) with the use of PC (cisplatin-based unless contraindicated, at which point a carboplatin-based regimen was provided) (121). Recruitment was halted early due to the significant PFS improvement seen with the AC arm. Although the official paper has yet to be published, the results of POUT are the strongest level 1 evidence supporting PC with UTUC. However, it is not without its limitations. Inclusion criteria were surgically staged pT2–4 and N0–3, or pT1 and N+, and who were fit for AC. As such, all patients who were chemotherapy-ineligible were excluded, leading to significant selection bias for only healthy patients. Notably, although statistically underpowered to evaluate, there still was a survival benefit of the carboplatin subset of patients; a similar survival benefit of carboplatin in UCB is not seen.

Although promising results, POUT still leaves questions unanswered.

<p>| Table 5 Outcomes of NAC for UTUC |</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>NAC (n) Regimen [n]</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rajput 2011 (119)</td>
<td>82</td>
<td>26 MVAC [6], CGI [5], MVAC &amp; bevacizumab [4], GTA [4], IAG [2], GC [2], GT [2]</td>
<td>LND performed more frequently with NAC No diff in EBL, transfusion rate, LOS</td>
</tr>
<tr>
<td>Leow* 2014 (102)</td>
<td>1,782</td>
<td>154 MVAC, GC, CGI, other</td>
<td>NAC with DFS: HR 0.41 (0.22–0.76)</td>
</tr>
<tr>
<td>Porten 2014 (103)</td>
<td>112</td>
<td>31 MVAC, GC, or CGI [21], GTA [7], IAG [3]</td>
<td>NAC 5-year DSS =90% vs. no NAC 58%, P=0.0204 NAC 5-year OS =80% vs. no NAC 58%, P=0.0015</td>
</tr>
<tr>
<td>Kubota 2017 (112)</td>
<td>234</td>
<td>101 GCarbo [76], GC [21], other [4]</td>
<td>NAC on IVRS: HR =0.52, P=0.023 NAC on RFS: HR =0.57, P=0.021 NAC on OS: HR =0.62, P=0.081</td>
</tr>
<tr>
<td>Almassi 2018 (106)</td>
<td>6,174</td>
<td>260 Not reported</td>
<td>NAC vs. no NAC on PR: 25% vs. 2%, P&lt;0.001</td>
</tr>
<tr>
<td>Hosogoe 2018 (109)</td>
<td>233</td>
<td>55 GC or GCarbo</td>
<td>5-year PFS NAC vs. no NAC: 60% vs. 39%, P=0.018 5-year CSS NAC vs. no NAC: 71% vs. 54%, P=0.015 5-year OS NAC vs. no NAC: 65% vs. 50%, P=0.032</td>
</tr>
<tr>
<td>Kim* 2019 (111)</td>
<td>318</td>
<td>– GC, GCarbo, MVAC, other</td>
<td>NAC relative improvement in PFS, CSS, and OS: 45%, 59%, 57% NAC effect on downstaging: OR =0.21 (0.27–0.57)</td>
</tr>
</tbody>
</table>

*, denotes systematic review/meta-analysis. NAC, neoadjuvant chemotherapy; UTUC, upper tract urothelial carcinoma; MVAC, methotrexate, vinblastine, Adriamycin, cisplatin; CGI, cisplatin, gemcitabine, ifosfamide; GTA, gemcitabine, paclitaxel, doxorubicin; IAG, ifosfamide, doxorubicin, gemcitabine; GC, gemcitabine, cisplatin; GT, gemcitabine, paclitaxel; GCarbo, gemcitabine, carboplatin; LND, lymph node dissection; EBL, estimated blood loss; LOS, length of stay; DFS, disease-free survival; HR, hazard ratio; DSS, disease-specific survival; IVRS, intravesical recurrence free survival; PR, pathologic response; OR, odds ratio; PFS, progression-free survival.
The efficacy of PC with NU remains unclear. Prospective RCTs are needed with appropriate inclusion and exclusion criteria, with an intention to treat analysis, especially with a NAC trial.

### Outcomes

The ONU is the gold standard of management for UTUC and has been since its conception nearly 100 years ago (9). However, the advent of the LNU, HALNU, and RANU

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>AC [n]</th>
<th>Regimen</th>
<th>Outcomes</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hellenthal 2009 (97)</td>
<td>542</td>
<td>121</td>
<td>MVAC [65], GC [22], other [23]</td>
<td>CSS with AC: HR =0.93 (0.93–1.71) OS with AC: HR =1.06 (0.80–1.40) Cisplatin-based AC associated with improved DFS, OS</td>
<td>AC not associated with improved CSS or OS</td>
</tr>
<tr>
<td>Leow* 2014 (99)</td>
<td>1,782</td>
<td>482</td>
<td>–</td>
<td>OS with AC (cisplatin-based): HR =0.43 (0.21–0.89) DFS with AC (cisplatin-based): HR =0.49 (0.24–0.99)</td>
<td>No benefit with non-cisplatin-based AC</td>
</tr>
<tr>
<td>Yafi 2014 (98)</td>
<td>1,029</td>
<td>–</td>
<td>GC, GCarbo</td>
<td>AC on CSS: HR =0.775 (0.401–1.496) AC on OS: HR =0.695 (0.290–1.663) AC associated with improved CSS for pN+ patients</td>
<td>AC did not improve OS or CSS</td>
</tr>
<tr>
<td>Fujita 2015 (102)</td>
<td>74</td>
<td>45</td>
<td>GC, GCarbo</td>
<td>5-year RFS AC vs. no AC: 34% vs. 14% (P=0.014) 5-year CSS AC vs. no AC: 43% vs. 12%, P=0.0003</td>
<td>AC associated with improved CSS for pN+ patients</td>
</tr>
<tr>
<td>Shirotake 2015 (101)</td>
<td>873</td>
<td>129</td>
<td>MVAC, GC</td>
<td>MVAC 1-year &amp; 2-year RFS: 71% &amp; 48% GC 1-year &amp; 2-year RFS: 48% &amp; NR No AC 1-year &amp; 2-year RFS: 53% &amp; 40%</td>
<td>MVAC associated with improved RFS over GC or no AC</td>
</tr>
<tr>
<td>Aziz* 2017 (104)</td>
<td>2,131</td>
<td>694</td>
<td>MVAC, MEC, MVEC, GC, other</td>
<td>–</td>
<td>Meta-analysis not performed, but review shows associated with AC and CSS and OS</td>
</tr>
<tr>
<td>Nakagawa 2017 (110)</td>
<td>109</td>
<td>43</td>
<td>MVAC, GC</td>
<td>Multivariate analysis: AC on RFS: HR =0.41, P=0.0178 AC on CSS: HR =0.33, P=0.0375 AC associated with improved RFS and CSS with pT3–4 UTUC</td>
<td>AC associated with improved RFS and CSS with pT3–4 UTUC</td>
</tr>
<tr>
<td>Seisen 2017 (112)</td>
<td>3,253</td>
<td>762</td>
<td>–</td>
<td>5-year OS AC vs. no AC =44% vs. 36% (P&lt;0.001) AC on OS: HR =0.77 (0.68–0.88)</td>
<td>AC associated with improved OS for pT3–4 and/or pN+</td>
</tr>
<tr>
<td>Ikeda 2018 (107)</td>
<td>449</td>
<td>100</td>
<td>MVAC [44], GC [42], other cisplatin-based regimens [14]</td>
<td>High-risk UTUC 5-year CSS AC vs. no AC: 29% vs. 14%, P=0.02</td>
<td>AC associated with improved CSS (but not DFS) for high-risk UTUC</td>
</tr>
<tr>
<td>Necchi 2018 (113)</td>
<td>1,544</td>
<td>312</td>
<td>Cisplatin-based [148], carboplatin-based [27], non-platinum-based [22], not reported [115]</td>
<td>AC on OS: HR =1.14 (0.91–1.43) AC did not improve OS compared with observation</td>
<td>AC did not improve OS compared with observation</td>
</tr>
</tbody>
</table>

* denotes systematic review. AC, adjuvant chemotherapy; MVAC, methotrexate, vinblastine, Adriamycin, cisplatin; CSS, cancer-specific survival; HR, hazard ratio; OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; GC, gemcitabine, cisplatin; GCarbo, gemcitabine, carboplatin; NR, not reached; MEC, methotrexate, etoposide, cisplatin; MVEC, methotrexate, vinblastine, epirubicin, cisplatin; UTUC, upper tract urothelial carcinoma.
has led to many studies comparing their outcomes.

**ONU vs. LNU**

The ONU and LNU have been compared extensively, mostly in retrospective reviews, but some prospective data exist. In a large multi-institutional review of 1,249 cases, Capitanio et al. reported that there was no difference in cancer recurrence and mortality between ONU and LNU (122). However, they conceded that the patients who underwent LNU generally had lower stage tumors and more favorable tumor locations (e.g., renal pelvis) than those receiving ONU. In one of the few prospective randomized trials comparing ONU and LNU, somewhat similar findings were noted. Simone et al. conducted a small randomized prospective study, randomizing 40 patients to ONU and 40 to LNU. They found no difference between IVRS, CSS, and MFS; however, when matched for pT3 disease and high-grade tumors, CSS and MFS was better with ONU versus LNU (11). In a systematic review of 42 studies by Peyronnet et al., poorer CSS and OS were noted with LNU for locally advanced (pT3–4) or high-grade disease, or laparoscopic approach to bladder cuff management (123).

Large systematic reviews and meta-analyses largely show oncologic equivalency between ONU and LNU, with some caveats. Ni et al. published on 21 studies from 2000 to 2011, of which all but one were retrospective in nature, and analysis revealed 9% improved 5-year CSS as well as improved IVRS with LNU, but otherwise no difference in 2-year CSS, 5-year RFS, 5-year OS, and metastasis rates (124). Similar to Capitanio et al., Ni et al. reported that pTa/Tis disease was significantly more common in LNU patients compared to ONU. A more recent systematic review and meta-analysis by Liu et al. found equivalent oncologic outcomes between ONU and LNU, regardless of tumor stage or grade (125). Both Liu and Ni found that LNU was associated with a longer operative time, but shorter overall LOS and lower EBL (124,125). Despite that, Liu failed to find a difference in perioperative complications between ONU and LNU. It is important to remember that although LNU allows for a more minimally invasive approach, a larger extraction incision is still required to remove the specimen en bloc.

When the HALNU is also considered, and compared to the LNU and ONU, similar equivalencies are seen. Nouralizadeh et al. performed a systematic review and meta-analysis of 52 studies (19,195 patients) and found no differences between 5-year CSS, OS, and RFS rates among LNU, HALNU, and ONU, as well as no difference between IVRS and metastasis rate. Similar to the systematic reviews and meta-analyses of LNU vs. ONU, LNU was associated with longer operative time when compared to ONU and HALNU, but shorter LOS and EBL (126).

Despite the evidence suggesting that LNU is oncologically equivalent to ONU, concerns still have been raised about its safety. As noted above, some data suggest that for higher grade or stage tumors, or ureteral tumors, LNU may be inferior to ONU (127). Furthermore, early reports raised concerns about port site seeding with LNU (128). However, systematic reviews and meta-analyses have not shown this to be demonstrated in other studies (125).

**ONU vs. LNU vs. RANU**

There are a number of studies comparing the three major surgical approaches for NU, but only one RCT. Some data suggest that ONU tends has a shorter operative time but longer LOS and higher EBL when compared to LNU or RANU (30). However, other studies have found either no difference, or a minimal difference in operative times (e.g., mean difference 10 minutes) (10,129). In an NCDB study of 9,401 patients who underwent NU (3,199 ONU, 2,098 RANU, 4,104 LNU), Rodriguez et al. found that LND is more likely to be performed with RANU (OR 1.51) and less likely in LNU (OR 0.77), but RANU was associated with a lower rate of positive surgical margins when compared to LNU (OR 0.73) (130). Despite the improved margin rate and rate of LND with RANU, use of the robot has been shown to be costlier when compared to LNU ($23,235 vs. $17,637) (14). Mullen et al. performed a systematic review of 50 studies comparing outcomes of ONU, LNU, and RANU, finding no difference in operative time among all three approaches, but did note lower EBL and shorter LOS for LNU compared to ONU (10). Mullen does mention that relative to ONU and LNU, there is a paucity of long-term outcomes data for RANU, but what is published shows that RANU appears to have similar efficacy to ONU and LNU. Notably, despite the aforementioned differences, the only RCT performed showed no statistically significant difference in survival outcomes between ONU and LNU, and most other studies also show no differences in survival outcomes among any of the three approaches (10,30,129,130).
Future developments

Despite the existence of the NU for over 100 years, there still are many questions to be answered. Prospective data for many of the issues described above are lacking; but that is quickly changing. At time of this publication, the manuscript describing the POUT trial is anxiously awaited. Prospective trials examining timing of perioperative intravesical chemotherapy are being performed to assess both efficacy as well as timing (pre-, intra-, or post-NU). Additionally, exciting developments with immunotherapy, currently specifically with UCB, are rapidly changing the management of bladder cancer and remains an area ripe for study with UTUC. The NU for UTUC has a long-standing history in urology and has evolved throughout the years; the future continues to become the present at a rapidly increasing rate.

Conclusions

NU is the standard of care for high-grade UTUC. Although some data suggest a survival benefit to PC with NU, there still are data arguing the opposite. Intravesical chemotherapy appears to improve IVRS, but there is still reticence among many Urologists to adopt its use, and trials are underway to elucidate optimal timing and agent use. Limited data support the use of LND for survival benefit, although it does appear that LND improves prognosis. There are LND templates that appear to be beneficial and a complete, templated dissection should be performed. If an LND is planned, the RANU tends to have a higher LNY than the LNU. However, overall there is not a clear consensus of oncologic superiority of a specific surgical approach.

Acknowledgments

The authors would like to thank Megan Llewellyn for her talented hand with designing the figures in this article.

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editor (Shomik Sengupta) for the series “Surgery for Urologic Cancers” published in Translational Andrology and Urology. The article has undergone external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2019.12.07). The series “Surgery for Urologic Cancers” was commissioned by the editorial office without any funding or sponsorship. Dr. Tan reports grants from National Cancer Institute - Ruth L. Kirschstein NRSA Institutional Research Training Grant (T32CA093245), outside the submitted work. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions relating to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

Int 2011;108:1708-13; discussion 1714.


